VTAKCatheter Precision, Inc.
The Read
VTAK’s stock initially rose about 28% after Q1 2026 earnings matched EPS estimates and Flyte’s network activation, but then plunged nearly 63% amid CMS reimbursement uncertainty and lack of relevant positive news.
The schedule
- Fri5Feb
- Fri30Apr
- Sat15May
Past
- Mon10Aug
Actual outcome: Bear
Catheter Precision reported Q2 2026 EPS of -$3.32, exactly meeting analyst estimates. Despite positive updates from its subsidiary Flyte, including record July revenues of $640,000 and a new AI partnership with Volato, the stock fell well below the $0.90 bear floor. The market remained focused on the company's wide ongoing losses and a lack of meaningful updates regarding its core catheter commercialization, driving the bearish price action.
Q2 2026 results will update the pace of catheter adoption and any benefit from prior regulatory and reimbursement developments, with shares likely to move from $1.21 toward $1.80 if revenue acceleration and improved gross margins signal a credible scaling trajectory, or toward $1.80 if growth stalls and losses remain wide.
- Sat25Jul
Actual outcome: Bear
Catheter Precision announced a series of partnerships for its Flyte subsidiary, including agreements with Blade Urban Air Mobility, 319 Golf Society, and LDV at The Maidstone. While these commercial developments drove a 10.4% rise in the stock from the event date to the outcome date, shares still closed at $0.29, remaining far below the $0.60 bear floor as overarching concerns regarding the company's limited cash runway and the threat of highly dilutive financing kept the valuation severely depressed.
Given Catheter Precision’s limited cash and ongoing losses, a potential equity financing or at-the-market issuance in mid-2026 would likely pressure the stock from $1.21 toward $1.30 if viewed as distressed and highly dilutive, with a best case of $1.30 if investors see the capital raise as sufficient to de-risk commercialization through key milestones.
- Fri10Jul
Actual outcome: Bear · $0.29 at outcome
VTAK shares plummeted 62.9% to $0.29, falling well below the $0.70 bear floor. While the market was focused on the CMS 2027 EP reimbursement proposal, the provided news only highlighted unrelated developments regarding Flyte's booking platform and a LifeVac partnership. In the absence of favorable reimbursement updates or relevant company-specific catalysts, the stock suffered a severe sell-off.
The mid-2026 CMS proposal for 2027 reimbursement on electrophysiology procedures will shape hospitals’ capital spending appetite for AF ablation tools, with Catheter Precision’s shares likely to drift from $1.21 toward $1.50 if rates are stable or favorable for EP labs, or toward $1.50 if proposed cuts signal structural pressure on procedure volumes or pricing.
- Mon18May
Actual outcome: Bull · $0.87 at outcome
Catheter Precision reported Q1 EPS of -$3.32, exactly matching estimates, and announced the activation of high-frequency flight networks through its Flyte subsidiary to capture peak travel demand. Although the stock initially rose 4.8% following the updates, the absence of stronger liquidity assurances ultimately weighed on shares, causing the price to drift lower and break the $0.80 bear floor by early July.
Q1 2026 results and management commentary on cash runway, debt, and sales traction for Catheter Precision’s electrophysiology devices are likely to drive a repricing from $1.21 toward either $1.70 if revenue growth holds near recent trends and liquidity looks secure into 2027, or toward $1.70 if losses stay elevated and the company signals a near-term need to raise capital.
